Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

A summary of current health news including Cigna's profit decline, Robert F. Kennedy Jr.'s Senate hearings, an Ebola outbreak ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Weber, one of the highest-profile foreign CEOs in Japan, spearheaded Takeda's $59 billion takeover of British-founded Shire ...

DelveInsight's Inflammatory Bowel disease market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...

Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK), celebrates the ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...